• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于环氧琥珀酰抑制剂的抑制活性-结合模式关系,通过复合物的X射线晶体结构分析对组织蛋白酶B的每个催化亚位点的抑制活性进行定量评估。

Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.

作者信息

Watanabe Daiya, Yamamoto Atsushi, Tomoo Koji, Matsumoto Keita, Murata Mitsuo, Kitamura Kunihiro, Ishida Toshimasa

机构信息

Department of Physical Chemistry, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara,Takatsuki, Osaka 569-1094, Japan.

出版信息

J Mol Biol. 2006 Oct 6;362(5):979-93. doi: 10.1016/j.jmb.2006.07.070. Epub 2006 Aug 1.

DOI:10.1016/j.jmb.2006.07.070
PMID:16950396
Abstract

To quantitatively estimate the inhibitory effect of each substrate-binding subsite of cathepsin B (CB), a series of epoxysuccinyl derivatives with different functional groups bound to both carbon atoms of the epoxy ring were synthesized, and the relationship between their inhibitory activities and binding modes at CB subsites was evaluated by the X-ray crystal structure analyses of eight complexes. With the common reaction in which the epoxy ring of inhibitor was opened to form a covalent bond with the SgammaH group of the active center Cys29, the observed binding modes of the substituents of inhibitors at the binding subsites of CB enabled the quantitative assessment of the inhibitory effect of each subsite. Although the single blockage of S1' or S2' subsite exerts only the inhibitory effect of IC50 = approximately 24 microM (k2 = approximately 1250 M(-1) s(-1)) or approximately 15 microM (k2 = approximately 1800 M(-1) s(-1)), respectively, the synchronous block of both subsites leads to IC50 = approximately 23 nM (k2 = 153,000 - 185,000 M(-1) s(-1)), under the condition that (i) the inhibitor possesses a P1' hydrophobic residue such as Ile and a P2' hydrophobic residue such as Ala, Ile or Pro, and (ii) the C-terminal carboxyl group of a P2' residue is able to form paired hydrogen bonds with the imidazole NH of His110 and the imidazole N of His111 of CB. The inhibitor of a Pn' > or = 3' substituent was not potentiated by collision with the occluding loop. On the other hand, it was suggested that the inhibitory effects of Sn subsites are independent of those of Sn' subsites, and the simultaneous blockage of the funnel-like arrangement of S2 and S3 subsites leads to the inhibition of IC50 = approximately 40 nM (k2 = approximately 66,600 M(-1) s(-1)) regardless of the lack of Pn' substituents. Here we present a systematic X-ray structure-based evaluation of structure-inhibitory activity relationship of each binding subsite of CB, and the results provide the structural basis for designing a more potent CB-specific inhibitor.

摘要

为了定量评估组织蛋白酶B(CB)每个底物结合亚位点的抑制作用,合成了一系列环氧琥珀酰衍生物,这些衍生物的环氧环的两个碳原子上连接有不同的官能团,并通过八个复合物的X射线晶体结构分析评估了它们在CB亚位点的抑制活性与结合模式之间的关系。在抑制剂的环氧环打开并与活性中心Cys29的SγH基团形成共价键的常见反应中,观察到的抑制剂取代基在CB结合亚位点的结合模式使得能够对每个亚位点的抑制作用进行定量评估。尽管单独阻断S1'或S2'亚位点仅分别产生IC50约为24μM(k2约为1250 M-1 s-1)或约15μM(k2约为1800 M-1 s-1)的抑制作用,但在以下条件下,两个亚位点的同步阻断导致IC50约为23 nM(k2 = 153,000 - 185,000 M-1 s-1):(i)抑制剂具有P1'疏水残基如Ile和P2'疏水残基如Ala、Ile或Pro,以及(ii)P2'残基的C末端羧基能够与CB的His110的咪唑NH和His111的咪唑N形成配对氢键。Pn'≥3'取代基的抑制剂不会因与封闭环碰撞而增强抑制作用。另一方面,表明Sn亚位点的抑制作用与Sn'亚位点的抑制作用无关,并且无论是否缺乏Pn'取代基,同时阻断S2和S3亚位点的漏斗状排列都会导致IC50约为40 nM(k2约为66,600 M-1 s-1)的抑制作用。在此,我们展示了基于X射线结构的对CB每个结合亚位点的结构-抑制活性关系的系统评估,结果为设计更有效的CB特异性抑制剂提供了结构基础。

相似文献

1
Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.基于环氧琥珀酰抑制剂的抑制活性-结合模式关系,通过复合物的X射线晶体结构分析对组织蛋白酶B的每个催化亚位点的抑制活性进行定量评估。
J Mol Biol. 2006 Oct 6;362(5):979-93. doi: 10.1016/j.jmb.2006.07.070. Epub 2006 Aug 1.
2
Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.E-64及其衍生物对半胱氨酸蛋白酶抑制作用的结构基础
Biopolymers. 1999;51(1):99-107. doi: 10.1002/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R.
3
Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.在1.9埃分辨率下测定的弹性蛋白酶特异性抑制剂elafin与猪胰弹性蛋白酶的晶体结构。
Biochemistry. 1996 Sep 10;35(36):11570-6. doi: 10.1021/bi960900l.
4
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.明胶酶催化结构域的同源性建模及新型磺胺类抑制剂的对接模拟
J Med Chem. 1999 May 20;42(10):1723-38. doi: 10.1021/jm980514x.
5
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.基于三肽的α-酮杂环作为凝血酶抑制剂的深入研究。S1'亚位点的有效利用及其对基于结构的药物设计的意义。
J Med Chem. 2005 Mar 24;48(6):1984-2008. doi: 10.1021/jm0303857.
6
Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.新型、强效的基于酮酰胺的组织蛋白酶K抑制剂的P2 - P3吡咯烷衍生物。
Bioorg Med Chem Lett. 2006 Mar 15;16(6):1735-9. doi: 10.1016/j.bmcl.2005.11.101. Epub 2006 Jan 11.
7
Exploring inhibitor binding at the S' subsites of cathepsin L.探索组织蛋白酶L的S'亚位点处的抑制剂结合情况。
J Med Chem. 2008 Mar 13;51(5):1361-8. doi: 10.1021/jm701190v. Epub 2008 Feb 16.
8
Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.血管紧张素I转化酶(ACE)抑制剂中区域选择性配体结合模式及原子水平药效团优化
Chembiochem. 2005 Jun;6(6):1089-103. doi: 10.1002/cbic.200400386.
9
The binding mode of an E-64 analog to the active site of cathepsin B.一种E-64类似物与组织蛋白酶B活性位点的结合模式。
Protein Eng. 1996 Nov;9(11):977-86. doi: 10.1093/protein/9.11.977.
10
A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.一种涉及活性位点多中心短氢键网络的新型丝氨酸蛋白酶抑制基序。
J Mol Biol. 2001 Apr 13;307(5):1451-86. doi: 10.1006/jmbi.2001.4516.

引用本文的文献

1
Nature-Inspired Gallinamides Are Potent Antischistosomal Agents: Inhibition of the Cathepsin B1 Protease Target and Binding Mode Analysis.受自然启发的 Gallinamides 是有效的抗血吸虫药物:对组织蛋白酶 B1 蛋白酶靶标的抑制作用及结合模式分析。
ACS Infect Dis. 2024 Jun 14;10(6):1935-1948. doi: 10.1021/acsinfecdis.3c00589. Epub 2024 May 17.
2
Targeting Cathepsin B for Cancer Therapies.靶向组织蛋白酶B用于癌症治疗
Horiz Cancer Res. 2015;56:23-40.
3
Theoretical insight into the mechanism for the inhibition of the cysteine protease cathepsin B by 1,2,4-thiadiazole derivatives.
1,2,4-噻二唑衍生物抑制半胱氨酸蛋白酶组织蛋白酶B机制的理论洞察
J Mol Model. 2014 Jun;20(6):2254. doi: 10.1007/s00894-014-2254-0. Epub 2014 Jun 1.
4
Cysteine cathepsins: from structure, function and regulation to new frontiers.半胱氨酸组织蛋白酶:从结构、功能与调控到新前沿领域
Biochim Biophys Acta. 2012 Jan;1824(1):68-88. doi: 10.1016/j.bbapap.2011.10.002. Epub 2011 Oct 12.
5
Structural basis for inhibition of cathepsin B drug target from the human blood fluke, Schistosoma mansoni.曼氏血吸虫(Schistosoma mansoni)组织蛋白酶 B 药物靶点抑制的结构基础。
J Biol Chem. 2011 Oct 14;286(41):35770-35781. doi: 10.1074/jbc.M111.271304. Epub 2011 Aug 10.
6
Multi-conformation 3D QSAR study of benzenesulfonyl-pyrazol-ester compounds and their analogs as cathepsin B inhibitors.苯磺酰基吡唑酯化合物及其类似物作为组织蛋白酶 B 抑制剂的多构象 3D QSAR 研究。
J Mol Graph Model. 2011 Sep;30:135-47. doi: 10.1016/j.jmgm.2011.06.013. Epub 2011 Jul 7.
7
QSAR models for predicting cathepsin B inhibition by small molecules--continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules.小分子对组织蛋白酶 B 抑制作用的定量构效关系模型——小分子对组织蛋白酶 B 抑制活性的连续和二元定量构效关系模型分类。
J Mol Graph Model. 2010 Jun;28(8):714-27. doi: 10.1016/j.jmgm.2010.01.009. Epub 2010 Feb 1.
8
Computational analysis of the cathepsin B inhibitors activities through LR-MMPBSA binding affinity calculation based on docked complex.基于对接复合物的 LR-MMPBSA 结合亲和力计算对组织蛋白酶 B 抑制剂活性的计算分析。
J Comput Chem. 2009 Nov 15;30(14):2165-75. doi: 10.1002/jcc.21214.